Lactobacillus reuteri targets farnesoid X receptor-dependent bile acid homeostasis to ameliorate alcoholic liver disease
The ISME Journal · 14.01.2026 · 20 (1)
DOI: 10.1093/ismejo/wrag153 ↗Kurz gefasst
Fachartikel in der Zeitschrift The ISME Journal, online erschienen am 16.06.2026. Verfasst von Shuo Yuan und 11 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, No. 38, Xueyuan Road, Haidian District, B…. Hauptthemen laut MEDLINE: Limosilactobacillus reuteri, Receptors, Cytoplasmic and Nuclear, Bile Acids and Salts, Liver Diseases, Alcoholic. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Project of Xinjiang, National Natural Science Foundation of China.
Abstract (Originalsprache)
Alcoholic liver disease (ALD) is characterized by gut dysbiosis, yet the functional contribution of specific commensals remains largely unexplored. Here, we identify a significant reduction of Lactobacillus reuteri in both ALD patients and mouse models compared with their respective healthy controls. Using fecal microbiota transplantation, we first establish a causative role of the dysbiotic gut microbiota in driving ALD pathophysiology. In line with this finding, oral supplementation with L. reuteri ameliorates ALD phenotypes. Mechanistically, L. reuteri activates the farnesoid X receptor (FXR) signaling pathway, thereby restoring bile acid homeostasis, as evidenced by reduced levels of cholic acid (CA) and deoxycholic acid (DCA). The functional importance of FXR is further validated in Fxr−/− mice, where the protective effects of L. reuteri on both ALD and bile acid metabolism are largely abrogated. Moreover, both in vitro and in vivo experiments confirm that CA and DCA directly compromise hepatocyte viability and exacerbate liver injury, reinforcing their roles as pathogenic effectors downstream of FXR dysregulation. Expanding upon these mechanistic insights, we identify the natural compound echinacoside as a gut microbiota-targeting intervention that not only enriches L. reuteri but also potentiates FXR signaling, leading to significant improvement of ALD. Collectively, our findings define a microbiota-host metabolic axis centered on L. reuteri and FXR-dependent bile acid homeostasis, offering a conceptual framework for targeting host–microbe interactions in ALD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, No. 38, Xueyuan Road, Haidian District, Beijing 100191, China.
- Beijing Institute of Heart Lung and Blood Vessel Disease, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chaoyang District, Beijing 100029, China.
- Department of Gastroenterology, Affiliated Hospital of Beihua University, No. 12, Jiefang Middle Road, Chuanying District, Jilin City, Jilin Province 132011, China.
Förderung
- Key Research and Development Project of Xinjiang
- National Natural Science Foundation of China
Zitieren
APA
Yuan, S., Liu, Y., Gao, P., Sun, J., Wang, Y., Du, Z., Lei, J., Hong, J., Fang, X., Tu, P., Lu, Y., & Jiang, Y. (2026). Lactobacillus reuteri targets farnesoid X receptor-dependent bile acid homeostasis to ameliorate alcoholic liver disease. The ISME Journal, 20(1). https://doi.org/10.1093/ismejo/wrag153
Vancouver
Yuan S, Liu Y, Gao P, Sun J, Wang Y, Du Z, et al. Lactobacillus reuteri targets farnesoid X receptor-dependent bile acid homeostasis to ameliorate alcoholic liver disease. The ISME Journal. 2026;20(1). doi:10.1093/ismejo/wrag153
BibTeX
@article{Yuan2026,
author = {Yuan, Shuo and Liu, Yuhua and Gao, Peng and Sun, Jiaxu and Wang, Yuanshi and Du, Zhiyong and Lei, Jun and Hong, Jiaxin and Fang, Xinlan and Tu, Pengfei and Lu, Yingyuan and Jiang, Yong},
title = {Lactobacillus reuteri targets farnesoid X receptor-dependent bile acid homeostasis to ameliorate alcoholic liver disease},
journal = {The ISME Journal},
year = {2026},
volume = {20},
number = {1},
doi = {10.1093/ismejo/wrag153}
}
EUVIMED